Analysis on the correlation of Fn14 and JAK/STAT signal pathway in non-small cell lung cancer with EG-FR exon 19 deletion

YANG Sanhu; YANG Feng; ZHANG Zhipei; SUN Ying; HUANG Lijun; WANG Lei; ZHONG Daixing; LI Xi-aofei

Abstract：Objective To explore the expression of fibroblast growth factor-inducible 14 ( Fn14 ) and Janus kinase/signal transducerand activator of transcription (JAK/STAT) in non-small cell lung cancer (NSCLC) tissues with EGFR exon 19 deletion. Methods In this study, 125 NSCLC cases with EGFR 19-Del were selected by amplification refractory mutation system. And the 30 cases of paired adjacent normal tissues were collected. Expressions of Fn14, p-JAK1 and p-STAT1 were detected in these samples using immunohistochemistry and the correlation of Fn14 expression with JAK/STAT expression was analyzed by statistics. Results The ex-pression of Fn14 was mainly located on cell membrane and cytoplasm, while the expression of p-JAK1 and p-STAT1 were mainly loca-ted in cytoplasm and cell nucleus. Compared to normal lung tissues, the higher expression rates of Fn14, p-JAK1 and p-STAT1 protein were 100. 0% ( 125/125) , 83. 2% ( 104/125) and 100. 0% ( 125/125) in NSCLC tissues with EGFR 19-Del ( P<0. 05) . There were significant differences of Fn14, p-JAK1 and p-STAT1 expression in histological grades, pTNM stages and lymph node metastasis ( P<0. 05) , while there were no significant differences in sex, age, smoking history and pathological types ( P>0. 05) . The correlation of Fn14 with p-JAK1 and p-STAT1 were obvious ( P<0. 05, r>0. 3) in pathological classification, histological grads and pTNM stage of NSCLC. Conclusion Fn14, p-JAK1 and p-STAT1 proteins are highly expressed in NSCLC with EGFR 19-Del, suggesting that the a-bove three proteins would be likely to associate with the development of NSCLC. The good correlations between Fn14 expression and p-JAK1, p-STAT1 hints that Fn14 may effect on the expression of p-JAK1, p-STAT1. All these provide important basis for the mecha-nism study of Fn14 affecting on the development of NSCLC with EGFR 19-Del.